Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
<p>Abstract</p> <p>Background</p> <p>Progressive remodeling after myocardial infarction (MI) is a leading cause of morbidity and mortality. Recently, glucagon-like peptide (GLP)-1 was shown to have cardioprotective effects, but treatment with GLP-1 is limited by its sho...
Main Authors: | van Gilst Wiek H, Meissner Maxi, Silljé Herman HW, Yin Meimei, de Boer Rudolf A |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-09-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://www.cardiab.com/content/10/1/85 |
Similar Items
-
Mild acute pancreatitis with vildagliptin use
by: Ravikant Saraogi, et al.
Published: (2012-01-01) -
Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson’s Disease
by: Ramesh Pariyar, et al.
Published: (2022-02-01) -
PROSPECTS OF NEPHROPROTECTION AGAINST TYPE 2 DIABETES USING THE DPP-4 INHIBITOR VILDAGLIPTIN
by: V. K. Bayrasheva, et al.
Published: (2017-12-01) -
Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report
by: Serhat Sayin, et al.
Published: (2018-03-01) -
EFFECT OF PHARMACOLOGICAL PRECONDITIONING WITH INCRETINOMIMETICS EXENATIDE AND VILDAGLIPTIN ON THE SURVIVAL OF ISCHEMIC TISSUES
by: Alla Tarasova, et al.
Published: (2017-12-01)